GANAB as a Novel Biomarker in Multiple Sclerosis: Correlation with Neuroinflammation and IFI35
Multiple sclerosis (MS) still lacks reliable biomarkers of neuroinflammation predictive for disease activity and treatment response. Thus, in a prospective study we assessed 55 MS patients (28 interferon (IFN)-treated, 10 treated with no-IFN therapies, 17 untreated) and 20 matched healthy controls (...
Saved in:
Main Authors: | Roberto De Masi, Stefania Orlando |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/cf5ad9c582db4e58845a5c6cfa3c41cd |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review
by: Sylwia Pietrasik, et al.
Published: (2021) -
Multiple sclerosis international
Published: (2010) -
TRPM2 contributes to neuroinflammation and cognitive deficits in a cuprizone-induced multiple sclerosis model via NLRP3 inflammasome
by: Yu Shao, et al.
Published: (2021) -
Factors associated with oral fingolimod use over injectable disease- modifying agent use in multiple sclerosis
by: Jagadeswara Rao Earla, et al.
Published: (2021) -
Primary Peripheral Epstein-Barr Virus Infection Can Lead to CNS Infection and Neuroinflammation in a Rabbit Model: Implications for Multiple Sclerosis Pathogenesis
by: Asma Hassani, et al.
Published: (2021)